<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574210</url>
  </required_header>
  <id_info>
    <org_study_id>BILA 2507/EEC</org_study_id>
    <secondary_id>P2FZ07001</secondary_id>
    <nct_id>NCT00574210</nct_id>
  </id_info>
  <brief_title>PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-Arm)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, 5-Arm Parallel Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Steady State Efficacy of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in the Treatment of the Symptoms of Seasonal Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Mode</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faes Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allied Research International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Faes Farma, S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the relative efficacy of four dosing regimens of
      bilastine tablets versus placebo in subjects with SAR exposed in controlled ragweed pollen
      using the EEC model based on the mean change from baseline in Total Nasal Symptom Scores
      (TNSS). Study includes male and female subjects, aged 18 and 65 years with clinical history
      of SAR with seasonal onset and offset of nasal allergy symptoms during each of the last two
      ragweed allergy seasons and a positive skin prick test to ragweed allergen within 12 months
      prior to randomization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Nasal Symptom Scores (TNSS)</measure>
    <time_frame>within 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Scores (TSS), Total Non-Nasal Symptom Scores (TNNSS), Total Ocular Symptoms Scores (TOSS), Area Under the Curve (AUC) of TNSS, TSS, TOSS, TNNSS, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ - EEC)</measure>
    <time_frame>witin 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <condition>Hay Fever</condition>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral twice per day (2 placebo tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bilastine</intervention_name>
    <description>Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Tablets administered twice per day</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical history of SAR for the last two ragweed allergy seasons.

          -  A positive skin test within 12 months of screening to ragweed allergen.

          -  A minimum qualifying symptom score on both Visits, 2 and 3.

          -  Females must have a confirmed absence of pregnancy according to a negative urine
             pregnancy test.

        Exclusion Criteria:

          -  Women who are pregnant, breastfeeding, or planning a pregnancy.

          -  History of more than mild asthma.

          -  History of clinically significant (as determined by the Investigator) active perennial
             allergic rhinitis to which the subject is regularly exposed.

          -  Non-allergic rhinitis (vasomotor or rhinitis medicamentosa).

          -  An anatomic abnormality that interferes with assessment of nasal function. - History
             of clinically significant recurrent sinusitis or chronic sinusitis. - Clinically
             significant (as determined by the Investigator) cardiovascular, hepatic, neurologic,
             psychiatric, endocrine, or other significant systemic disease that makes
             implementation of the protocol jeopardizing to the safety of the subject.

          -  A need for use of antihistamines or corticosteroids on a regular basis (systemic or
             topical).

          -  Currently taking monoamine oxidase (MAO) inhibitors.

          -  Taken any systemic corticosteroids, immunomodulators, or immune suppressive
             medications within four weeks prior to Visit 1.

          -  Taken any antihistamine within seven days prior to Visit 1 skin testing.

          -  Known current alcohol or drug abuse.

          -  Current participation in another clinical study involving an experimental treatment,
             or participation in such a study within 30 days prior to study entry. - History of
             generalized anaphylaxis requiring medical attention.

          -  Clinically significant abnormality of screening blood chemistry, hematology, or
             urinalysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Valiente, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Faes Farma, S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piyush Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allied Research International Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deepen Patel, MD, CCFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allied Research International Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allied Research International - Cetero Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>905-238-0599</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <last_update_submitted>January 9, 2009</last_update_submitted>
  <last_update_submitted_qc>January 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ander Sologuren, MD</name_title>
    <organization>Faes Farma, S.A.</organization>
  </responsible_party>
  <keyword>Seasonal Allergic Rhinitis (SAR)</keyword>
  <keyword>Environmental Exposure Chamber (EEC)</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Antihistamine Drug</keyword>
  <keyword>Ragweed Pollen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

